GGrantIndex
← Leaderboards

Erasmus Medical Center

Rotterdam

Compare ↔
$8,722,417
Total funding
8
Grants

Funding over time

peak $1.1M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,722,417 · 8

By mechanism

R01$5,207,364 · 3
R37$1,907,233 · 1
U01$1,240,134 · 2
R21$277,686 · 1
N02$90,000 · 1

Investigators at Erasmus Medical Center

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Mathilde Richard$1,196,0181 gr2Christopher Schliehe$277,6861 gr

Emerging Leaders

6–10 yrs in

1David Van De Vijver$2,523,8501 gr2Charles Achim Bernard Boucher$628,5721 gr

All-Time

Most funded here, all years

1David Van De Vijver$2,523,8501 gr2Mathilde Richard$1,196,0181 gr3Franklin G Grosveld$858,9241 gr4Charles Achim Bernard Boucher$628,5721 gr5Christopher Schliehe$277,6861 gr

Largest grants

Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice$676,315
R01 · FY2023 · AI
Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice$628,572
R01 · FY2019 · AI
Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice$614,205
R01 · FY2021 · AI
Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice$613,626
R01 · FY2020 · AI
Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice$606,316
R01 · FY2022 · AI
Unravelling highly pathogenic influenza virus emergence$473,525
R01 · FY2024 · AI
Unravelling highly pathogenic influenza virus emergence$384,665
R01 · FY2023 · AI
Unravelling highly pathogenic influenza virus emergence$337,828
R01 · FY2025 · AI
Characterization of the first HSCs during mouse ontogeny$303,760
R37 · FY2012 · DK
Characterization of the first HSCs during mouse ontogeny$291,846
R37 · FY2011 · DK
Investigating PROTAC-mediated antigen degradation as a novel strategy to enhance cytotoxic T-cell responses against cancer in vivo.$277,686
R21 · FY2022 · CA
Characterization of the first HSCs during mouse ontogeny$245,662
R37 · FY2010 · DK
Characterization of the first HSCs during mouse ontogeny$243,021
R37 · FY2009 · DK
Characterization of the first HSCs during mouse ontogeny$241,089
R37 · FY2008 · DK
Characterization of the first HSCs during mouse ontogeny$237,927
R37 · FY2007 · DK
Molecular basis of human gamma-globin gene activation.$216,000
R01 · FY2003 · HL
Molecular basis of human gamma-globin gene activation.$216,000
R01 · FY2005 · HL
Molecular basis of human gamma-globin gene activation.$216,000
R01 · FY2004 · HL
Molecular basis of human gamma-globin gene activation.$210,924
R01 · FY2006 · HL
Characterization of the first HSCs during mouse ontogeny$207,236
R37 · FY2006 · DK